Skip to main content

Table 1 Demographic and clinical characteristics of PUC patients

From: Primary tumor surgery improves survival in non-metastatic primary urethral carcinoma patients: a large population-based investigation

Variable

Total (n = 1544)

Group A: No surgery of primary site (n = 403)

Group B: Local therapy (n = 532)

Group C: Radical surgery of primary site (n = 582)

p value

(A vs. B)

p value

(A vs. C)

p value

(B vs. C)

Age at diagnosis

    

0.142

<0.001*

<0.001*

 Mean (SD)

69.54 (13.03)

70.4 (13.52)

73.02 (12.85)

65.8 (11.89)

   

Race

    

0.001*

0.833

0.003*

 White

1164 (75.4)

288 (71.5)

431 (81.0)

422 (72.5)

   

 Black

290 (18.8)

84 (20.8)

81 (15.2)

121 (20.8)

   

 Other

90 (5.8)

31 (7.7)

20 (3.8)

39 (6.7)

   

Sex

    

<0.001*

0.903

<0.001*

 Male

971 (62.9)

233 (57.8)

385 (72.4)

333 (57.2)

   

 Female

573 (37.1)

170 (42.2)

147 (27.6)

249 (42.8)

   

Grade

    

<0.001*

<0.001*

<0.001*

 I

70 (5.1)

25 (6.2)

27 (5.1)

26 (4.5)

   

 II

290 (18.8)

70 (17.4)

84 (15.8)

130 (22.3)

   

 III

457 (29.6)

123 (30.5)

126 (23.7)

203 (34.9)

   

 IV

376 (24.4)

66 (16.4)

168 (31.6)

139 (23.9)

   

 Unknown

342 (22.2)

119 (29.5)

127 (23.9)

84 (14.4)

   

Histology

    

<0.001*

0.040*

<0.001*

 SCC

437 (28.3)

130 (32.2)

95 (17.9)

205 (35.2)

   

 TCC

660 (42.7)

146 (36.2)

305 (57.3)

198 (34.0)

   

 AC

252 (16.3)

59 (14.6)

77 (14.5)

111 (19.1)

   

 Other

195 (12.6)

68 (16.9)

55 (10.3)

68 (11.7)

   

T stage

    

<0.001*

<0.001*

<0.001*

 T0/T1

521 (33.7)

109 (27.0)

274 (51.7)

131 (22.5)

   

 T2

315 (20.4)

56 (13.9)

110 (20.8)

147 (25.3)

   

 T3

318 (20.6)

78 (19.4)

54 (10.2)

179 (30.8)

   

 T4

180 (11.7)

62 (15.4)

35 (6.6)

81 (13.9)

   

 Tx

207 (13.4)

97 (24.1)

57 (10.8)

44 (7.6)

   

N stage

    

<0.001*

<0.001*

<0.001*

 N0

1040 (67.5)

206 (51.2)

416 (78.5)

403 (69.2)

   

 N1

149 (9.7)

60 (14.9)

23 (4.3)

63 (10.8)

   

 N2

154 (10.0)

51 (12.7)

33 (6.2)

69 (11.9)

   

 Nx

198 (12.8)

85 (21.1)

58 (10.9)

47 (8.1)

   

M stage

    

<0.001*

<0.001*

0.041*

 M0

1245 (80.8)

258 (64.2)

451 (85.1)

517 (88.8)

   

 M1

158 (10.3)

96 (23.9)

38 (7.2)

22 (3.8)

   

 Mx

138 (9.0)

48 (11.9)

41 (7.7)

43 (7.4)

   

AJCC stage groups

    

<0.001*

<0.001*

<0.001*

 I

432 (28.2)

68 (16.9)

247 (47.0)

111 (19.2)

   

 II

228 (14.9)

38 (9.5)

84 (16.0)

104 (18.0)

   

 III

264 (17.2)

48 (11.9)

42 (8.0)

170 (29.4)

   

 IV

392 (25.6)

158 (39.3)

84 (16.0)

145 (25.1)

   

 Unknown

217 (14.2)

90 (22.4)

69 (13.1)

48 (8.3)

   

Tumor size, mm (n = 642)

   

<0.001*

0.041*

0.007*

 Mean (SD)

38.27 (24.31)

44.30 (24.18)

30.20 (19.82)

38.88 (25.01)

   

Radiation

    

<0.001*

<0.001*

0.641

 Yes

403 (26.1)

146 (36.2)

113 (21.2)

116 (19.9)

   

 No/Unknown

1141 (73.9)

257 (63.8)

419 (78.8)

466 (80.1)

   

Chemotherapy

    

<0.001*

0.006*

0.011*

 Yes

477 (30.9)

161 (40.0)

129 (24.2)

182 (31.3)

   

 No/Unknown

1067 (69.1)

242 (60.0)

403 (75.8)

400 (68.7)

   
  1. PUC Primary urethral carcinoma, AJCC American Joint Committee on Cancer